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British Journal of General Practice editorial: Which first-line antidepressant? 
 
Tony Kendrick Professor of Primary Care, Primary Care & Population Sciences, University of 
Southampton 
David Taylor Director of Pharmacy & Pathology, Maudsley Hospital, and Professor of 
Psychopharmacology, King’s College London  
Chris Johnson Antidepressant Specialist Pharmacist, NHS Greater Glasgow & Clyde Pharmacy & 
Prescribing Support Unit 
 
Choice of first-line antidepressants for depression has been in the news over the past year, in 
relation both to NICE’s on-line consultation on the proposed update of the 2009 NICE depression 
guideline [1], and the widely reported meta-analysis by Cipriani et al in the Lancet, comparing 21 
antidepressants for efficacy and tolerability [2].  
 
In its draft guidance for consultation, NICE recommends mirtazapine be considered a possible first-
line antidepressant for more severe depression, alongside the selective serotonin reuptake inhibitors 
(SSRIs) [1]. This is new in 2018, as the 2009 guideline did not recommend mirtazapine first-line [3].    
 
In a their network meta-analysis, Cipriani et al found that agomelatine, amitriptyline, escitalopram, 
mirtazapine, paroxetine, venlafaxine, and vortioxetine were more effective than other 
antidepressants [2]. They also found agomelatine, citalopram, escitalopram, fluoxetine, sertraline, 
and vortioxetine to be relatively more tolerable [2]. This suggests three antidepressants with higher 
efficacy might be preferable first-line choices given their relatively high acceptability: escitalopram, 
agomelatine, and vortioxetine.  
 
So should mirtazapine, escitalopram, agomelatine, and vortioxetine now be considered first-line for 
depression, along with the SSRIs? 
 
Both the new NICE recommendation and the Cipriani conclusions are based on network meta-
analysis (NMA): i.e. analysis in which multiple treatments are compared using both direct 
comparisons within randomised controlled trials, but also indirect comparisons across trials based 
on a common comparator. So, if antidepressants ‘A’ and ‘C’ have been compared to antidepressant 
‘B’ in trials, you can infer how ‘A’ would perform compared to ‘C’ through the NMA, even if ‘A’ and 
‘C’ have never been compared in the same trial. However, suggestions from NMAs that some 
antidepressants are more effective or more acceptable than others should be treated with caution, 
as their results are not always consistent with direct head-to-head comparisons. NMAs assume 
broad uniformity of studies and their participants and that optimal doses are always used. In reality 
none of these is true – further reason to treat outcomes with some suspicion. 
 
In its first draft update in 2017, NICE recommended mirtazapine first-line for less severe depression 
as well as for more severe. This was because mirtazapine ranked relatively highly in an NMA of 
interventions when looking at reduction in depressive symptoms (response) as an outcome 
(although not when looking at ‘remission’ for which there was a lack of evidence), and was relatively 
cost-effective too [1]. However, the recommendation for first line use for less severe depression was 
removed following the first consultation, during which concerns were raised about safety of 
mirtazapine, arising from general practice prescribing database studies.  In these studies, use of 
mirtazapine was found to be associated with statistically significant absolute increases in rates of 
suicide and self-harm when compared with treatment with SSRIs and with no antidepressant 
treatment [4].  The updated draft NICE guidance acknowledges these risks but points out that 
observational studies cannot separate the effects of patients’ underlying depression from any 
possible drug-related effect, especially as mirtazapine might preferentially be prescribed to patients 
with more severe depression. The full guidance states that the absolute increase in risk of suicide or 
self-harm for older people taking mirtazapine compared with those who did not take 
antidepressants was only 1.3%, and the recommendation of mirtazapine as an alternative to SSRIs 
for more severe depression remains [1].  
 
Turning to escitalopram, 2018 is not the first time Cipriani and colleagues have suggested that it 
should be considered first-line due to a combination of higher efficacy and higher tolerability. A 
previous network meta-analysis by the same group published in 2009, comparing 12 
antidepressants, stated that clinically important differences existed between antidepressants for 
both efficacy and acceptability, in favour of escitalopram and sertraline’ [5]. Following the 2009 
NMA, use of sertraline rose significantly while the use of citalopram levelled off, and that of 
fluoxetine fell [6]. However, escitalopram use did not increase significantly [6].  That may have been 
because of the relatively higher cost of escitalopram which was still under patent at that time, but 
since then its cost has fallen to a level similar to other more popular antidepressants [7].   
 
So why not escitalopram first-line? One reason is concern about safety, as, like citalopram, it is 
known to prolong the electrocardiogram QTc interval, leading to an increased risk of arrhythmia in 
overdose, which led to a warning about its use from the Medicines and Healthcare Regulatory 
Agency (MHRA) in 2011. In contrast, sertraline has been shown to be safe when used in patients 
with cardiac problems, for example after myocardial infarction.  Another reason is that the superior 
efficacy of escitalopram has been demonstrated most convincingly in studies involving rats, not 
humans. In humans, pharmaceutical company funded direct comparisons have tended to use 
relatively low doses of SSRIs (e.g. sertraline 100-150mg) or serotonin-norepinephrine reuptake 
inhibitors (SNRIs) (e.g. venlafaxine 75-150mg) as comparators when testing efficacy, and relatively 
high doses of SSRIs (e.g. fluoxetine 60mg) as comparators when testing tolerability [8]. There is still a 
relative lack of direct head-to-head trial evidence for escitalopram’s claimed superiority over other 
antidepressants, apart from citalopram [8].  
Agomelatine is thought to act through a combination of antagonist activity at 5HT2C receptors and 
agonist activity at melatonergic MT1/MT2 receptors, which makes it unique among  antidepressants, 
as it does not affect the reuptake of serotonin, norepinephrine (noradrenaline), or dopamine. A 
systematic review of direct head-to-head studies comparing it with standard antidepressants found 
it had similar efficacy to standard antidepressants, although published trials generally had more 
favourable results than unpublished studies [9]. Given a year’s treatment costs £390 compared to £7 
for fluoxetine, £9 for serotonin, £13 for escitalopram and £30 for citalopram [7], agomelatine should 
currently be limited to a third-line choice, but it is a viable alternative to other antidepressants when 
poor tolerability or contraindications preclude the use of SSRIs, SNRIs, and mirtazapine.  
Vortioxetine is a serotonin transporter blocker which increases the extracellular concentration of 
serotonin, dopamine and noradrenaline, and so acts like an SNRI. A 2017 Cochrane review found no 
advantage when it was compared with SNRIs, being less effective than duloxetine, although it had 
less severe adverse effects [10]. The review criticised a relative lack of direct head-to-head 
comparisons between vortioxetine and the SSRIs, and the reliance placed on the results of NMAs to 
define its role [10]. Given a year’s treatment costs £360, vortioxetine also should remain a third-line 
choice – as recommended by the NICE HTA of vortioxetine 
 
So how should GPs choose a first-line antidepressant?  Current NICE guidance [1, 3] and the British 
Association of Pharmacology (BAP) [11], suggest an SSRI should be considered first, unless there is a 
history of poor response or unacceptable side effects with SSRIs, in which case mirtazapine is an 
alternative if sedation and stimulation of appetite are desired effects, or else a tricyclic or tricyclic 
related drug such as nortriptyline or lofepramine if sedation is to be avoided. Older tricyclics should 
be reserved for when first-line treatment has failed, and monoamine oxidase inhibitors should only 
be prescribed by experts. 
 
There are relatively few differences between SSRIs, although paroxetine is best avoided unless 
patients particularly ask for it, given its short half-life which leads to a greater risk of discontinuation 
symptoms, and its somewhat greater tendency to cause sexual dysfunction and weight gain. 
Sertraline is probably a safer choice than citalopram, escitalopram or fluoxetine in patients with 
heart disease particularly if overdose is a possibility, although it causes diarrhoea more often. 
Important interactions to beware include paroxetine attenuation of the benefits of tamoxifen; 
fluoxetine potentiation of the seizure risk with clozapine; and fluvoxamine potentiation of the 
effects of theophylline and clozapine, through inhibition of hepatic cytochrome P450 enzymes. 
Fluoxetine can also lead to serotonin syndrome when taken together with tramadol. 
 
SSRIs as a class increase the risk of gastrointestinal, uterine and cerebral bleeding, particularly when 
taken with aspirin or non-steroidal anti-inflammatories, and so should be avoided by patients with 
dyspepsia, or given together with a protein pump inhibitor. They are also more likely to cause 
hyponatraemia especially for patients taking diuretics. For patients with these relative 
contraindications mirtazapine, nortriptyline or lofepramine would be a better first choice.  
If patients have, in a prior episode of depression, tried SSRIs without response, mirtazapine or an 
SNRI would be a better first choice (venlafaxine or duloxetine rather than vortioxetine in the first 
instance). If they have had no response to previous treatment courses of SSRIs, mirtazapine and 
SNRIs, then agomelatine would be a reasonable choice.   
 
The BAP guidelines state that useful pharmacogenetic predictors of response to antidepressants are 
not available, and that there is very limited evidence for any personal or family history being of use 
in predicting a differential response to different antidepressants, but that considering patients’ 
preferences improves treatment adherence and may improve outcomes [11].  
 
It should in any case be borne in mind that antidepressant treatment is best avoided if possible [12] 
and should only be prescribed if psychological interventions or exercise have either been tried first 
or are thought to be unsuitable, or if the patient has recurrent depression and is asking for drug 
treatment, or the patient is at risk of developing more severe depression (e.g. they have a history of 
severe depression).  
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